Another name under-$10 name in the biotechnology and drugs complex that looks poised for much higher prices is
(RPTP - Get Report)
. Raptor's product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. This stock is off to a decent start in 2012 with shares up over 6.5% so far.
If you take a look at the chart for Raptor Pharmaceutical, you'll see that this stock has been uptrending very strong since it marked a recent bottom at $3.66 a share last August. During that uptrend, RPTP has been consistently making higher lows and higher highs, which is bullish price action. Whenever any stock shows a pattern like this, it demonstrates that large institutional traders are paying up to own the stock whenever it dips.
Market players should now watch RPTP for a
trigger above $6.44 and then $7.06 on high-volume. At last check, RPTP has already taken out that overhead resistance level of $6.44 today and the volume on this move is very strong. Over 865,000 shares have traded so far, which is well above the three-month average volume of 435,653 shares.
Traders should now look for long biased trades in RPTP since the first breakout level over $6.44 a share has hit. One could be a buyer off any future weakness and simply use a mental stop right below some near-term support at $6.25 or down to $6 if you want to give it more room. I would then add aggressively to any long positions if $7.06 is taken out with volume. A high-volume move over $7.06 could lead to huge spike higher in this stock.
Shares of RPTP sport a decent short interest since over 9% of the tradable float is currently sold short by the bears. The short-sellers have also been increasing their bets from the last reporting period by 5.4%, or by about 234,000 shares. Those short-sellers will not be feeling very comfortable if RPTP takes out $7.06 soon, so look to squeeze them if that level is breached with volume.